
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : MiNK Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
MiNK And Autonomous Collaborate on Novel Therapies For Metastatic Tumors
Details : The collaboration will leverage Autonomous’ precision encRNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215, an investigational, off-the-shelf cellular immunotherapy, and agenT-797.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 08, 2024
Lead Product(s) : MiNK-215
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : MiNK Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration

Contact Us!